Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.74 HKD | +2.24% | +11.38% | -21.04% |
03:19pm | Sino Biopharm Completes Phase I Study of Hepatitis B Drug | MT |
Apr. 22 | Lull in Geopolitical Tensions Lifts Asian Stock Markets | MT |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company is in a robust financial situation considering its net cash and margin position.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.04% | 6.27B | B- | ||
+24.17% | 562B | B | ||
-6.31% | 358B | C+ | ||
+19.85% | 322B | B- | ||
+7.80% | 297B | C+ | ||
+13.45% | 219B | B+ | ||
+6.04% | 199B | B- | ||
-10.51% | 196B | A+ | ||
-12.07% | 149B | C+ | ||
-6.46% | 146B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 1177 Stock
- Ratings Sino Biopharmaceutical Limited